课题基金 / 基金详情

Paramyxovirus Entry

Paramyxovirus Entry
副粘病毒进入
批准号:
6400855
负责人:
Trudy G. Morrison
金额:
$31.47万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-30 至 2002-08-31

项目摘要

项目成果

Trudy G. Morrison的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of our studies is to understand the molecular mechanisms of paramyxovirus membrane fusion using Newcastle disease virus as a prototype. As in most paramyxovirus systems, membrane fusion requires both HN and F proteins. Our studies have focused on two questions, how the F protein mediates membrane fusion and the role of RN protein in that process. Our mutational analysis of the F protein has shown that two heptad repeat domains, HR1 and HR2, are important in the fusion activity of the protein. We have shown that peptides with sequences from these domains interact but likely only upon activation of fusion. We have also found that sequences from the HN protein will interact with a specific domain within the F protein. Furthermore, we have made a point mutation within another F protein heptad repeat domain, HR3, which eliminated the absolute requirement for RN protein in fusion. To address the questions raised by these findings we propose four specific aims: 1) To determine limits of HN protein and F protein interacting domains. 2) To characterize the interactions of peptides and peptide analogues from the HR1, HR2, and RN sequences in order to clarify mechanisms involved in fusion inhibition by F mutants, to identify residues important for conformational shifts, and to identify residues important in RN-F protein interactions. 3) To define the nature of conformational shifts in the glycoproteins using peptides, peptide analogues, as well as peptide specific antisera. 4). To explore the role attachment in initiation of fusion.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of an RSV vaccine for the elderly
Development of an RSV vaccine for the elderly
Development of an RSV vaccine for the elderly
Role of F Protein Conformation in RSV Vaccine Efficacy
海外基金